Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

10.35 -1.09 (-9.53%)
Streaming Delayed Price Updated: 12:28 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
From NeoGenomics, Inc.
Via Business Wire
News headline image
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack
Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers. 
Via StockStory
News headline image
Q4 Testing & Diagnostics Services Earnings: RadNet (NASDAQ:RDNT) Impresses
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting... 
Via StockStory
News headline image
Demystifying NeoGenomics: Insights From 6 Analyst Reviews ↗
 
Via Benzinga
News headline image
5 Analysts Assess NeoGenomics: What You Need To Know ↗
 
Via Benzinga
News headline image
Evaluating NeoGenomics: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
3 Reasons to Sell NEO and 1 Stock to Buy Instead
NeoGenomics has gotten torched over the last six months - since September 2024, its stock price has dropped 36.8% to $9.98 per share. This may have investors wondering how to approach the situation. 
Via StockStory
News headline image
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
From NeoGenomics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 18, 2025 ↗
 
Via Benzinga
News headline image
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst... 
Via StockStory
News headline image
3 Small-Cap Stocks in Hot Water
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks Skating on Thin Ice
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
News headline image
What To Expect From RadNet’s (RDNT) Q4 Earnings
Diagnostic imaging company RadNet (NASDAQ:RDNT) will be reporting results tomorrow after market hours. Here’s what to look for. 
Via StockStory
News headline image
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
News headline image
Why NeoGenomics (NEO) Shares Are Trading Lower Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall... 
Via StockStory
News headline image
NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, the... 
Via StockStory
News headline image
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. 
Via StockStory
News headline image
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
From NeoGenomics, Inc.
Via Business Wire
News headline image
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
News headline image
Earnings Scheduled For February 18, 2025 ↗
 
Via Benzinga
News headline image
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance ↗
The company expects sales to grow 12% to 13% annually in the long term. 
Via Investor's Business Daily
News headline image
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
From NeoGenomics, Inc.
Via Business Wire
News headline image
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
NeoGenomics Shares Are Falling Today: What's Going On? ↗
Shares of NeoGenomics, Inc. (NASDAQ: NEO) are, after the company announced that CEO Chris Smith will retire effective April 1 2025. 
Via Benzinga
News headline image
NeoGenomics Announces Chief Executive Officer Succession
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.